Market report: ResMed announces record quarterly results
Friday, 28 January, 2011
ResMed (ASX:RMD), maker of sleep and respiratory medical devices, announced today record revenue and income for the last quarter of 2010, although investors in the ASX took 2.5% off the company's stock price in morning trading.
The company posted a revenue for the quarter ending December 31, 2010, of US$306 million, which is up 11% on the same quarter for 2009, largely on the back of sales of its S9 AutoSet sleep therapy system.
The lion's share of the growth occurred in the European and Asia-Pacific regions, which saw a 12% year-on-year growth, or 17% at a constant currency basis. Growth in the United States was lower, at 10%.
Expenses also increased over the quarter, primarily due to increased demand for sales support.
Research and development expenses were US$22 million, or 7% of revenue, an increase of 15% (or 10% at constant currency) year-on-year.
Even with the positive revenue news, investors on the ASX were drove down the price of ResMed shares by 2.5% in early trading, although they bounced back at midday to around $3.18, down 1.85% on Thursday's close.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
